Science-led · Regulation-fluent · Africa-rooted
Mishonga is a phytopharmaceutical and cannabinoid development platform connecting African bio-resources to regulated global markets — from seed to shelf, compliantly.
Why Mishonga
We integrate botanical science, regulatory compliance, and global distribution into a single end-to-end offering.
Science-led formulation from Africa's richest botanical resources.
From African cultivation to compliant global export — fully integrated.
Regulatory fluency that opens doors to the world's most demanding markets.
About Mishonga
Mishonga is a next-generation botanical and cannabinoid platform focused on developing high-value phytopharmaceutical and nutraceutical products for regulated global markets.
We operate at the intersection of African botanical heritage and cutting-edge pharmaceutical science — unlocking the continent's extraordinary biodiversity for the benefit of global health and wellness markets.
Based in South Africa with a primary export focus on the German and broader European market, Mishonga brings together cultivation, processing, formulation, regulatory compliance, and distribution into a single vertically integrated offering.
To position Africa as a leading global supplier of compliant, high-quality plant-based therapeutics and wellness products — turning biodiversity into a sustainable economic asset.
CBD, CBG & hemp derivatives — formulated to global pharmaceutical standards with full traceability.
Leveraging Africa's unique phytochemical IP — rooibos, buchu, devil's claw, moringa and more.
Nutraceuticals, functional foods, personal care — formulated for the modern health consumer.
Low-impact extraction, closed-loop systems and carbon-conscious production aligned with ESG mandates.
Unique biodiversity · Cost-effective production · Untapped phytochemical IP · Sustainable agroecosystems.
Products & Solutions
From cannabinoid APIs to finished consumer products — manufactured to GMP standards and export-ready.
Innovation & Sustainability
Our innovation platform goes beyond product development — we're building a circular bioeconomy where botanical production, carbon capture, and pharmaceutical value creation reinforce each other.
Using hemp and selected botanical species to remediate degraded soils, capture carbon, and generate high-value biomass inputs for pharmaceutical processing.
Full utilisation of plant biomass — active compounds for pharma, residual biomass for biochar, seed for propagation, and crop rotation for soil health.
Low-impact supercritical CO₂ and ethanol extraction. Closed-loop solvent recovery. Energy-efficient operations designed to minimise environmental footprint.
Carbon Value Chain
Carbon Credit Project
Mishonga is pioneering carbon credit integration for GMP-certified cannabinoid facilities and finished-product manufacturing — a first-mover opportunity in the intersection of pharmaceutical compliance and sustainability.
We are seeking an experienced Carbon Credit Project Lead to spearhead carbon quantification, verification, and credit generation across our GMP-certified manufacturing and product value chain. This role will establish Mishonga as a benchmark for sustainable pharmaceutical production in Africa.
Carbon baseline establishment, energy audit, renewable transition roadmap & verified emission reduction credits
Scope 1–3 emissions mapping, sustainable sourcing credits, product lifecycle carbon accounting
Product carbon footprint certification, carbon-neutral labelling strategy, consumer-facing sustainability claims
Sustainable packaging transition, biodegradable material sourcing, circular packaging credit programmes
Soil carbon sequestration quantification, certified biochar carbon credits (Puro.earth & VCS standards)
Multiple interlocking carbon monetisation pathways across the Mishonga value chain — from cultivation to finished goods.
Multiple StreamsHemp and botanical crop cultivation as verified carbon sinks. Eligible under Verra VCS, Gold Standard, and South African voluntary carbon market frameworks.
VCS · Gold StandardRenewable energy procurement, process efficiency improvements, and verified emission reductions from GMP-certified pharmaceutical and nutraceutical manufacturing facilities.
ISO 14064 · ISCC+Permanent carbon sequestration via biochar produced from processing biomass residues. High-value credits eligible on Puro.earth and premium voluntary markets.
Puro.earth · CDR CreditsCarbon-neutral and low-carbon labelling for finished pharmaceutical, nutraceutical, and FMCG product lines — enabling premium market positioning in EU and UK.
EU Taxonomy · PAS 2060"Carbon is not just a compliance obligation — it is a commercial opportunity. Mishonga is building this into our core business model from day one."
Discuss Carbon PartnershipMarket Access & Compliance
Our export model is built on regulatory fluency, GMP compliance, and established distribution partnerships in priority markets.
SAHPRA-compliant product registration, GMP certification, section 22C licences, and cannabis scheduling compliance for legal export.
EMA alignment, EU-GMP certification, Novel Food authorisation for CBD products, and country-specific import compliance for Germany, Netherlands, and Nordics.
DHL pharmaceutical logistics, GDP-compliant cold chain, EU distribution hub partnerships, and direct-to-pharmacy supply agreements.
Ongoing ADR monitoring, PSUR preparation, label lifecycle management, and regulatory intelligence for both SA and EU markets.
Strategic Geography
Production hub, GMP processing, SAHPRA compliance, and export gateway
Primary EU market entry — largest medical cannabis market in Europe
EU distribution hub, logistics gateway, and secondary market
Pharma, nutraceutical & wellness sectors worldwide
Export Model
Partnerships
We Work With
Partnership Opportunities
Co-develop product lines or manufacturing capabilities with equity participation
Access our GMP-certified manufacturing for your branded product requirements
Exclusive or non-exclusive distribution of Mishonga products in your territory
R&D partnerships for novel extraction, formulation, or carbon technology development
"Let's build the African phytopharma value chain together."
Become a PartnerFor Investors
Mishonga operates at the intersection of four high-growth global sectors — creating a uniquely diversified and defensible investment thesis.
Investment Thesis — Market Intersection
EUR 3.2B European market by 2025 — Germany leading legalisation
Global nutraceutical market $722B by 2030 — 8.9% CAGR
SA uniquely positioned as low-cost, compliant supplier to EU
VCM projected $50B+ by 2030 — biochar & pharma first movers
Revenue Streams
Growth Strategy
Formulation, GMP certification, SAHPRA registration, initial product range
Germany market entry, EU-GMP certification, distribution partnerships
Own cultivation, expanded manufacturing, white-label scale-up, carbon credit launch
Licensing agreements, JVs with global pharma, carbon market full activation
Insights
Germany's cannabis legalisation reshapes the EU market. We examine what it means for African exporters and how to position now for first-mover advantage.
Read More →Africa hosts 25% of the world's botanical diversity, yet less than 2% of global botanical drug revenue. Why this is changing — and who will capture the opportunity.
Read More →How pharmaceutical hemp cultivation can generate verified carbon removal credits — and why GMP facility carbon accounting is the next frontier in sustainable pharma.
Read More →A practical guide to SAHPRA scheduling, GMP certification, EU Novel Food compliance, and what South African producers need to know before their first export shipment.
Read More →Contact Us
Whether you're a partner, investor, cultivator, or institution — we want to hear from you.
We respond within one business day.
South Africa
EU presence: Germany
Products, supply chain, white-label
JVs, distribution, collaboration
Carbon credit project lead role, partnerships
Funding, deck, due diligence